Page 16 - CIRN Annual Report 2017

in Spring 2018. The study, Immunization of children with primary
Enrollment and follow up are ongoing and results are expected
for ALL and determine the safety and immunogenicity of DTaP-
IPV-Hib and pneumococcal immunization after chemotherapy.

immune defi ciencies (PID) aims to describe the attitudes and practices of immunologists, pediatricians and infectious disease specialists caring for children with PID, and to estimate vaccine coverage and timeliness among children diagnosed with PID before age 7. Recruitment started in February 2017 and results are expected in Fall 2017.

contraindications to immunization study across 6 provinces and has
vaccine safety, effectiveness and coverage in immunocompromised
AEFI and potential contraindications to immunization, and evaluates
immunization in patients with mild to moderate AEFI and those with
The Special Immunization Clinics (SIC) Network conducts
standardized assessments of patients with medically challenging
built a national registry of patients assessed and their outcomes
Special Immunization
The network continues the Immunizing patients with AEFI and
Clinics (SIC) Network
after revaccination. Results to date support the safety of re-

potential contraindications. The network also supports two multi-center studies: Vaccinating children after chemotherapy for acute lymphoblastic leukemia (ALL) aims to identify risk factors for low vaccine titres in children treated

patients. 14